Characterization of HIV-1 entry inhibitors with broad activity against R5 and X4 viral strains
Francesca Sironi(Istituti di Ricovero e Cura a Carattere Scientifico), Priscilla Biswas(Mario Negri Institute for Pharmacological Research), Carles Martínez‐Romero(Icahn School of Medicine at Mount Sinai), Nicola Mongelli(Istituto Nazionale di Fisica Nucleare, Sezione di Milano), Mauro Malnati(Vita-Salute San Raffaele University), Paolo Lusso(National Institute of Allergy and Infectious Diseases), Christina Guzzo(National Institutes of Health), Daniela Jabés(CTI BioPharma (Italy)), Silvia Ghezzi(Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda), Paolo Cozzi(Nerviano Medical Sciences), Adolfo García‐Sastre(Office of Infectious Diseases)
Cited by 3
Related Papers
Influenza
|Nature Reviews Disease Primers|2018|1.5k
Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial
|The Lancet Oncology|2016|1k
Human host factors required for influenza virus replication
|Nature|2009|825
In vivo evolution of HIV-1 co-receptor usage and sensitivity to chemokine-mediated suppression
|Nature Medicine|1997|635